BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 27234729)

  • 1. Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.
    Thammanichanond D; Wiwattanathum P; Mongkolsuk T; Kantachuvesiri S; Worawichawong S; Vallipakorn SA; Kitpoka P
    Transplant Proc; 2016 Apr; 48(3):756-60. PubMed ID: 27234729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of C1q fixing donor-specific antibodies on renal transplant outcome.
    Baranwal AK; Goswami S; Agarwal SK; Kaur G; Mehra NK
    Scand J Immunol; 2021 Jul; 94(1):e13048. PubMed ID: 33914934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of C1q-fixing donor-specific antibodies after kidney transplantation.
    Thammanichanond D; Mongkolsuk T; Rattanasiri S; Kantachuvesiri S; Worawichawong S; Jirasiritham S; Kitpoka P
    Transplant Proc; 2014; 46(2):368-71. PubMed ID: 24655965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.
    Farrero Torres M; Pando MJ; Luo C; Luikart H; Valantine H; Khush K
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28940521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation.
    Ramon DS; Huang Y; Zhao L; Rendulic T; Park JM; Sung RS; Samaniego M
    Hum Immunol; 2017 Feb; 78(2):57-63. PubMed ID: 27894836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
    Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
    Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients.
    Fichtner A; Süsal C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Opelz G; Tönshoff B
    Pediatr Nephrol; 2016 Jul; 31(7):1157-66. PubMed ID: 26928311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.
    Zeevi A; Lunz J; Feingold B; Shullo M; Bermudez C; Teuteberg J; Webber S
    J Heart Lung Transplant; 2013 Jan; 32(1):98-105. PubMed ID: 23142561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.
    Kuppachi S; Holanda D; Gallegos S; Field EH
    Clin Transpl; 2016; 32():127-134. PubMed ID: 28564530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
    Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
    Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
    Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
    Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure.
    Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
    J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing.
    Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G;
    Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft Failure.
    Malheiro J; Santos S; Tafulo S; Dias L; Martins S; Fonseca I; Almeida M; Pedroso S; Beirão I; Castro-Henriques A; Cabrita A
    Transplantation; 2018 Nov; 102(11):1943-1954. PubMed ID: 29757900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.